-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下:我們將目標價下調7美元至53美元,並採用9.2倍的預期本益比(基於我們對2027年每股收益的預期),而PYPL過去三年的平均預期本益比為12.2倍,同業平均本益比為8.3倍。我們維持2026年每股收益預期為5.43美元,並將2027年的預期從5.95美元下調至5.78美元。新任執行長Lores在上任第一季推出了一項亟需的策略框架,將公司重組為三個獨立的業務部門,以提高專注度和責任感。該計畫以一項至少15億美元的重大成本節約計畫為基礎,並重新強調利用人工智慧實現技術架構的現代化。我們認為這是必要的根本性調整,管理層終於承認了過去的問題,並制定了一條清晰但充滿挑戰的前進道路。儘管公司重申了全年目標,但第二季業績指引疲軟,這更加凸顯了這種謹慎的展望。雖然核心品牌結帳業務成長依然乏力,但我們欣慰地看到Venmo和支付服務供應商(PSP)等其他業務領域持續保持強勁勢頭,為此次轉型提供了緩衝。
Related Articles
Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
Meitu Records 30% Rise in Paying Subscribers
Meitu (HKG:1357) said the number of paying subscribers using its platform grew 30% year on year to 17.90 million as of end March, according to a Hong Kong bourse filing Wednesday.Paying subscribers for the company's productivity tools grew 53% to 2.34 million, while leisure app subscribers increased 27% to 15.56 million, the firm said.The company's core revenue grew 34.3% year on year to 852 million yuan, while other businesses remained "stable overall."The company's annual recurring revenue for AI-driven productivity apps stood at 580 million yuan as of March, a 56% increase from a year earlier.
Yidu Tech Unit Wins SG$2.3 Million Singapore Healthcare Project
Yidu Tech (HKG:2158) said its subsidiary EVYD Research Private Limited won a contract from Singapore Health Services for the implementation and support of Dr Buddy, according to a Wednesday Hong Kong bourse filing.The total project amount is about SG$2.3 million.